Medscape is available in 5 Language Editions – Choose your Edition here.


Anorectal Abscess Treatment & Management

  • Author: Andre Hebra, MD; Chief Editor: John Geibel, MD, DSc, MSc, MA  more...
Updated: Dec 16, 2015

Approach Considerations

As a rule, the presence of an abscess is an indication for incision and drainage. Watchful waiting while administering antibiotics is inadequate. Clinical suspicion of anorectal abscess warrants aggressive identification and surgical incision and drainage. Delaying surgical intervention results in chronic tissue destruction, fibrosis, and stricture formation and may impair anal continence. Simple perianal abscesses may be treated in the emergency department (ED); more complex perirectal abscesses are treated by an experienced surgeon in an operating room.

Some surgeons advise performing a complementary colostomy to facilitate management of complex anal fistulas. This may be of some benefit in selected cases, but the perirectal infection may continue despite a diverting colostomy. Adequate drainage of the abscess is the most important factor in controlling progressive perirectal infection.

A patient with a perirectal abscess should be admitted to the surgical service unless other medical conditions or complications from the abscess necessitate a primary medical admission, with the surgeon acting as a consultant. Consider admitting a patient with a perirectal abscess to a medical service with the surgeon as a consultant should be considered if the patient is elderly, febrile, hypotensive, or immunocompromised or has significant comorbidities.

Transfer, if warranted, may be safely carried out if the patient is hemodynamically stable. Instability resulting from a concurrent condition or sepsis makes transfer to another institution inappropriate (and possibly illegal under the Emergency Medical Treatment and Active Labor Act [EMTALA]) unless transfer to allow delivery of a higher level of care is in the patient’s best interest.


Pharmacologic Therapy

The need for routine use of antibiotics in patients with anorectal abscesses has not been established; they have not been shown to improve healing times or reduce recurrence rates. In most of these patients, therefore, adjuvant medical therapy with antibiotics is considered unnecessary. However, concomitant use of antibiotics may be warranted in patients with conditions such as the following[1] :

  • Systemic inflammatory response or sepsis
  • Extensive cellulitis
  • Diabetes
  • Immunosuppression
  • Heart valve abnormalities or prostheses

Predisposing or comorbid factors may guide empiric antibiotic selection. If antibiotics are considered, the increasing prevalence of methicillin-resistant S aureus should be taken into account; according to a 2009 study, both vancomycin and trimethoprim-sulfamethoxazole provide excellent coverage.[9]


Surgical Intervention


Because of the acute nature of anorectal abscesses, preoperative bowel preparation is not possible and typically is unnecessary.

Tetanus immunity status should be ascertained. When acceptable immunity cannot be established, the currently recommended guidelines for high-risk wounds should be followed.

Adequate analgesia before aspiration is mandatory. Lidocaine 2% with epinephrine injected subcutaneously over and around the periphery of the abscess and intramuscular (IM) or intravenous (IV) narcotics are recommended. Ethylene chloride spray applied to the suspected area immediately before aspiration may also help decrease the discomfort of aspiration. The cooling effect of ethylene chloride renders pain receptors temporarily unable to transmit pain signals to the cerebral cortex.

Conscious is also an option if the physician is trained and prepared to manage the airway. If this route is taken, cardiac monitoring, pulse oximetry, and airway management equipment must be available, including suctioning devices, bag-valve-mask, and endotracheal intubation equipment. This technique should be used only by physicians highly skilled in cardiac and airway management.

Management of abscess

Treatment of anorectal abscesses involves early surgical drainage of the purulent collection.[32, 33, 34, 35, 36, 37, 38] Primary antibiotic therapy alone is ineffective in resolving the underlying infection and simply postpones surgical intervention. Any delay in surgical intervention prolongs infection and augments tissue damage, and it may impair sphincter continence function and promote stricture or fistula formation. The ability to drain an anorectal abscess depends on patient comfort and on the location and accessibility of the abscess.

When the abscess is perianal or superficial, drainage can usually be accomplished in the office or ED with local anesthesia. A small incision is made over the area of fluctuance; to shorten the length of any fistula that may form, the incision should be made as close to the anus as is compatible with safety.[1] Pus is collected and sent for culture. Hemostasis is achieved with manual pressure, and the wound is packed with iodophor gauze.

After 24 hours, the gauze is removed, and the patient is instructed to take sitz baths 3 times a day and after bowel movements. Postoperative analgesics and stool softeners are prescribed to relieve pain and prevent constipation. Typically, the patient follows up with the physician in 2-3 weeks for wound evaluation and inspection for possible fistula-in-ano. (A short fistula-in-ano coursing through a minimal amount of external sphincter is best treated with a fistulotomy.)

The formation of fistulous tracts (see below) is an important potential complication of anorectal abscess drainage. The type of organism cultured from an anorectal abscess is an important predictor of fistula formation after surgical incision and drainage. Underlying anal fistulas are present in 40% of abscess cultures that are positive for intestinal bacteria; however, cultures growing Staphylococcus species are associated with perianal skin infections and typically indicate that there is no risk of subsequent fistula formation.

Treatment of ischiorectal, intersphincteric, and supralevator abscesses typically requires general or regional anesthesia. To drain an ischiorectal abscess, a cruciate incision is made at the site of maximal swelling. Pus is drained and cultured. The ischiorectal fossa is probed with a finger or hemostat to disrupt loculations and facilitate drainage. Placement of a drain is indicated only for the management of complex or bilateral abscesses.

To drain an intersphincteric abscess, a transverse incision is made in the anal canal below the dentate line posteriorly. The intersphincteric space is identified, and the plane between the internal and external sphincters is exposed. The abscess is opened to allow drainage, and a small mushroom catheter is sutured in situ to assist drainage and prevent premature wound closure.

The optimal drainage technique for a supralevator abscess is determined by the location and etiology of the lesion. Failure to take the primary etiology into account in the management of a supralevator abscess may lead to iatrogenic fistula formation. Evaluation with magnetic resonance imaging (MRI) or computed tomography (CT) can exclude intra-abdominal or pelvic pathology as possible sources.

If the supralevator abscess evolved from the extension of an ischiorectal abscess, external drainage through the ischiorectal fossa would be indicated. If the abscess resulted from an upward extension of an intersphincteric abscess, appropriate drainage would be created through the rectal mucosa.

In cases of posterior supralevator abscess collections, a transverse incision is made in the posterior anal canal below the dentate line. The dissection extends from the intersphincteric plane through the puborectalis sling and into the posterior anal space. A mushroom catheter is then sutured in place to ensure adequate drainage.

Anterior supralevator abscesses are superficial and are more common in women than in men. Surgical drainage may be accomplished via an anteriorly directed transanal incision or by way of a transvaginal approach entering the posterior cul-de-sac. A mushroom catheter is placed to ensure adequate drainage of the abscess collection. Patients with systemic signs of toxicity are admitted to the hospital and treated with IV antibiotics.

If the patient’s clinical condition does not improve over the following 24-48 hours, reevaluation of the supralevator abscess by means of CT or reoperation may be indicated. Some patients with recurrent, severe supralevator abscesses may require a diverting colostomy for optimal management.[39]

Management of fistula

Although the anal fistula has been reported since the time of Hippocrates, there is little systematic evidence to establish optimal management. Different treatment modalities have been evaluated in more than 400 reported trials. Approaches that have been researched include the following:

  • Fistulotomy versus fistulectomy
  • Seton treatment [40]
  • Marsupialization
  • Glue therapy
  • Anal flaps
  • Radiosurgical approaches
  • Fistulotomy/fistulectomy at time of abscess incision
  • Intraoperative anal retractors

Two reported meta-analyses compared incision and drainage alone with incision plus fistulotomy. Evidence suggests that after fistulotomy, marsupialization reduces bleeding and permits faster healing. Results from small trials indicate that healing rates after flap repair may be no worse than those after fistulotomy, though this has not yet been proven.[41] Failure rates may be higher when flap repair has been combined with fibrin glue treatment of fistulas.[42]

Radiofrequency fistulotomy results in less pain on the patient’s first postoperative day and may permit faster healing.[43] However, a great deal is not yet understood about surgical treatment of anal fistulas.[35]

Decisive management of anal fistulas relies on therapeutic interventions. Healing rarely is spontaneous, and failure to achieve adequate treatment often results in recurrent abscess, persistent drainage, and even malignancy. The main paradigms to follow in the management of anorectal fistulas include the following:

  • Determine the anatomy of the fistula
  • Provide adequate drainage
  • Eradicate the fistula tract
  • Prevent recurrence
  • Preserve sphincter function (preservation depends on maintaining the integrity of the anorectal ring)

Once the external opening of the anorectal fistula has been identified and the surrounding tissue has been palpated, probing of the fistula tract is warranted. To prevent formation of false channels, aggressive probing is discouraged. By using a blunt probe (eg, a small lachrymal probe), the internal origin of a primary fistula can be identified in the majority of cases.

When one is searching for a fistula tract’s opening in the anal canal, the Goodsall rule is an excellent guideline. This rule states that an external opening anterior to a transverse line drawn across the anal verge is associated with a straight radial tract into the canal, whereas an external opening posterior to the transverse line follows a curved fistulous tract to the posterior midline rectal lumen (see the image below). Horseshoe fistulas occasionally are associated with anterior and posterior openings in the anal canal.

Goodsall rule for anorectal fistulas. Note curved Goodsall rule for anorectal fistulas. Note curved nature of posterior fistulas and radial (straight) orientation of anterior fistulas.

Treatment options for the management of fistulas are aimed at providing definitive therapy while minimizing the morbidity of the procedure. For example, two widely accepted treatment interventions are fistulectomy (removing the entire fistula tract along with the surrounding scar tissue) and fistulotomy (unroofing the tract without excising all surrounding tissue).

Studies have demonstrated that fistulectomy results in a larger wound, prolonged healing time, and higher risks of incontinence. As a result, the more conservative procedure, fistulotomy, is usually preferred; it decreases the risk of incontinence and fistula recurrence and also shortens wound healing time. Fistulotomy is performed as a primary procedure for superficial fistulas that require minimal dissection of the fistula from the surrounding sphincter musculature.

In contrast, simple fistulotomy is contraindicated as primary treatment of high-level (ie, transsphincteric and suprasphincteric) fistulas. For high-level fistulas, the use of loose setons is warranted to reduce the risk of incontinence or in cases where poor wound healing is anticipated.

Setons may also be used as temporary initial intervention in the management of a fistula. A seton is a nonabsorbable nylon or silk suture that is guided through the fistula tract and tied exteriorly, in this way compressing and maintaining suture placement in the tract. A soft vessel loop may also be used for seton placement. The seton suture must be left in place for a prolonged period (weeks to months).

The ischemic compression created by the seton and the local inflammatory reaction of adjacent tissues initiate fibrosis. Once fibrosis of the surrounding tissue develops, it helps to maintain the integrity of the sphincter musculature during subsequent fistulotomy. Setons often are used in patients with fistulas secondary to inflammatory bowel disease (IBD). In addition, setons allow epithelialization of the fistulous tract, thereby preventing secondary closure and facilitating the drainage of abscesses.

Another commonly used type of seton is the cutting seton, which can be used to gradually transect the anal sphincter musculature underlying the fistula by externally tightening the suture to induce pressure necrosis. Typically, the seton must be retightened over a period of several days; this can be done in the outpatient setting. Use of a cutting seton may eliminate the need for subsequent fistulotomy. Whereas the cutting seton can be an effective therapeutic option for high-level fistulas, it is contraindicated in patients with IBD.

Other treatment modalities include resection with coverage by advancement tissue flaps (used for more complex cases) and placement of a bioprosthetic fistula plug (made of porcine submucosa). The plug technique is indicated in selected cases with long fistulous tracts; the success rate is variable (50-70%).

Patients with anal fissures can be treated with topical nifedipine gel and onabotulinumtoxinA injections. Occasionally, sphincterotomy (incision of the lateral internal anal sphincter) may be necessary.

Postoperative care

Postoperatively, analgesics are given for pain, and stool bulking agents and stool softeners are given to prevent constipation. After appropriate wound care, patients may be discharged home with instructions for sitz baths and routine follow-up. Adequate outpatient analgesia (eg, codeine with acetaminophen or an oxycodone-containing compound) should be provided. Outpatient antibiotics may be indicated and are best chosen on the basis of culture and sensitivity testing of pathogens derived from the abscess.



Simple perianal abscesses can generally be managed in the ED. When the diagnosis of a more complex perirectal abscess is made or is being entertained, however, expeditious consultation with a surgeon is mandatory. Timely and appropriate operative treatment prevents more serious complications, such as extension of the abscess or serious systemic infection. Appropriate surgical treatment of perirectal abscess should not be undertaken in the ED. General or spinal anesthesia is necessary to obtain the optimal result.


Long-Term Monitoring

An otherwise healthy patient with a simple isolated perianal abscess may be treated in the ED with incision and drainage and released with timely follow-up care. If inpatient surgical treatment is required, surgical follow-up is necessary; acute abscesses recur in 10% of patients, and chronic fistula-in-ano may occur in as many as 50%.[1] Typically, the patient follows up with the physician in 2-3 weeks for wound evaluation and inspection for possible fistula-in-ano.

If any unusual symptoms arise, such as persistent pain or fever, patients should be advised to return immediately to the ED or to another provider.

Contributor Information and Disclosures

Andre Hebra, MD Chief, Division of Pediatric Surgery, Professor of Surgery and Pediatrics, Medical University of South Carolina College of Medicine; Surgeon-in-Chief, Medical University of South Carolina Children's Hospital

Andre Hebra, MD is a member of the following medical societies: Alpha Omega Alpha, Florida Medical Association, Society of American Gastrointestinal and Endoscopic Surgeons, Children's Oncology Group, International Pediatric Endosurgery Group, American Academy of Pediatrics, American College of Surgeons, American Medical Association, American Pediatric Surgical Association, Society of Laparoendoscopic Surgeons, South Carolina Medical Association, Southeastern Surgical Congress, Southern Medical Association

Disclosure: Nothing to disclose.

Chief Editor

John Geibel, MD, DSc, MSc, MA Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director, Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow

John Geibel, MD, DSc, MSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Received royalty from AMGEN for consulting; Received ownership interest from Ardelyx for consulting.


Marc D Basson, MD, PhD, MBA, FACS Professor, Chair, Department of Surgery, Assistant Dean for Faculty Development in Research, Michigan State University College of Human Medicine

Marc D Basson, MD, PhD, MBA, FACS is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Gastroenterological Association, Phi Beta Kappa, and Sigma Xi

Disclosure: Nothing to disclose.

Michael S Beeson, MD, MBA, FACEP Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine and Pharmacy; Attending Faculty, Akron General Medical Center

Michael S Beeson, MD, MBA, FACEP is a member of the following medical societies: American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Steven C Dronen, MD, FAAEM Chair, Department of Emergency Medicine, LeConte Medical Center

Steven C Dronen, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Eugene Hardin, MD, FAAEM, FACEP Former Chair and Associate Professor, Department of Emergency Medicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine, Martin Luther King Jr/Drew Medical Center

Disclosure: Nothing to disclose.

Nizar Kifaieh, MD, FACEP Assistant Professor, Medical Director, Department Of Emergency Medicine, State University of New York Downstate Medical Center

Nizar Kifaieh, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physician Executives, American Medical Association, New York County Medical Society, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Patrick B Thomas, MD Fellow, Department of Pediatric Surgery, Texas Children's Hospital

Disclosure: Nothing to disclose.

Walter W Valesky Jr, MD Clinical Assistant Instructor, Department of Emergency Medicine, Kings County Hospital, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

  1. Whiteford MH. Perianal abscess/fistula disease. Clin Colon Rectal Surg. 2007 May. 20(2):102-9. [Medline]. [Full Text].

  2. Marcus RH, Stine RJ, Cohen MA. Perirectal abscess. Ann Emerg Med. 1995 May. 25(5):597-603. [Medline].

  3. Pfenninger JL, Zainea GG. Common anorectal conditions: Part II. Lesions. Am Fam Physician. 2001 Jul 1. 64(1):77-88. [Medline].

  4. Rizzo JA, Naig AL, Johnson EK. Anorectal abscess and fistula-in-ano: evidence-based management. Surg Clin North Am. 2010 Feb. 90(1):45-68, Table of Contents. [Medline].

  5. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976 Jan. 63(1):1-12. [Medline].

  6. Hamadani A, Haigh PI, Liu IL, Abbas MA. Who is at risk for developing chronic anal fistula or recurrent anal sepsis after initial perianal abscess?. Dis Colon Rectum. 2009 Feb. 52(2):217-21. [Medline].

  7. Brook I, Frazier EH. The aerobic and anaerobic bacteriology of perirectal abscesses. J Clin Microbiol. 1997 Nov. 35(11):2974-6. [Medline]. [Full Text].

  8. Albright JB, Pidala MJ, Cali JR, Snyder MJ, Voloyiannis T, Bailey HR. MRSA-related perianal abscesses: an underrecognized disease entity. Dis Colon Rectum. 2007 Jul. 50(7):996-1003. [Medline].

  9. Brown SR, Horton JD, Davis KG. Perirectal abscess infections related to MRSA: a prevalent and underrecognized pathogen. J Surg Educ. 2009 Sep-Oct. 66(5):264-6. [Medline].

  10. Beard JM, Osborn J. Anorectal Abscess. Rakel RE, Rakel DP, eds. Textbook of Family Medicine. 8th ed. Philadelphia, Pa: Saunders; 2011.

  11. Novotny NM, Mann MJ, Rescorla FJ. Fistula in ano in infants: who recurs?. Pediatr Surg Int. 2008 Nov. 24(11):1197-9. [Medline].

  12. Hämäläinen KP, Sainio AP. Incidence of fistulas after drainage of acute anorectal abscesses. Dis Colon Rectum. 1998 Nov. 41(11):1357-61; discussion 1361-2. [Medline].

  13. Athanasiadis S, Köhler A, Nafe M. Treatment of high anal fistulae by primary occlusion of the internal ostium, drainage of the intersphincteric space, and mucosal advancement flap. Int J Colorectal Dis. 1994 Aug. 9(3):153-7. [Medline].

  14. Abbas MA, Lemus-Rangel R, Hamadani A. Long-term outcome of endorectal advancement flap for complex anorectal fistulae. Am Surg. 2008 Oct. 74(10):921-4. [Medline].

  15. Hyman N, O'Brien S, Osler T. Outcomes after fistulotomy: results of a prospective, multicenter regional study. Dis Colon Rectum. 2009. 52:2022-7. [Medline].

  16. Weizberg M, Gillett BP, Sinert RH. Penile discharge as a presentation of perirectal abscess. J Emerg Med. 2008 Jan. 34(1):45-7. [Medline].

  17. Smereck J, Ybarra M. Acute hip pain and inability to ambulate: a rare presentation for perirectal abscess. Am J Emerg Med. 2011 Mar. 29(3):356.e1-3. [Medline].

  18. Bennetsen DT. Perirectal abscess after accidental toothpick ingestion. J Emerg Med. 2008 Feb. 34(2):203-4. [Medline].

  19. Erhan Y, Sakarya A, Aydede H, Demir A, Seyhan A, Atici E. A case of large mucinous adenocarcinoma arising in a long-standing fistula-in-ano. Dig Surg. 2003. 20(1):69-71. [Medline].

  20. Fish D, Kugathasan S. Inflammatory bowel disease. Adolesc Med Clin. 2004 Feb. 15(1):67-90, ix. [Medline].

  21. [Guideline] Whiteford MH, Kilkenny J 3rd, Hyman N, Buie WD, Cohen J, Orsay C, et al. Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum. 2005 Jul. 48(7):1337-42. [Medline].

  22. Sözener U, Gedik E, Kessaf Aslar A, Ergun H, Halil Elhan A, Memikoglu O, et al. Does adjuvant antibiotic treatment after drainage of anorectal abscess prevent development of anal fistulas? A randomized, placebo-controlled, double-blind, multicenter study. Dis Colon Rectum. 2011 Aug. 54(8):923-9. [Medline].

  23. Chandwani D, Shih R, Cochrane D. Bedside emergency ultrasonography in the evaluation of a perirectal abscess. Am J Emerg Med. 2004 Jul. 22(4):315. [Medline].

  24. Tio TL, Mulder CJ, Wijers OB, et al. Endosonography of peri-anal and peri-colorectal fistula and/or abscess in Crohn's disease. Gastrointest Endosc. 1990 Jul-Aug. 36(4):331-6. [Medline].

  25. Caliste X, Nazir S, Goode T, Street JH 3rd, Hockstein M, McArthur K, et al. Sensitivity of computed tomography in detection of perirectal abscess. Am Surg. 2011 Feb. 77(2):166-8. [Medline].

  26. Berton F, Gola G, Wilson SR. Sonography of benign conditions of the anal canal: an update. AJR Am J Roentgenol. 2007 Oct. 189(4):765-73. [Medline].

  27. Stewart LK, McGee J, Wilson SR. Transperineal and transvaginal sonography of perianal inflammatory disease. AJR Am J Roentgenol. 2001 Sep. 177(3):627-32. [Medline].

  28. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR. Clinical examination, endosonography, and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. Radiology. 2004 Dec. 233(3):674-81. [Medline].

  29. Domkundwar SV, Shinagare AB. Role of transcutaneous perianal ultrasonography in evaluation of fistulas in ano. J Ultrasound Med. 2007 Jan. 26(1):29-36. [Medline].

  30. Berman L, Israel GM, McCarthy SM, Weinreb JC, Longo WE. Utility of magnetic resonance imaging in anorectal disease. World J Gastroenterol. 2007 Jun 21. 13(23):3153-8. [Medline].

  31. Waniczek D, Adamczyk T, Arendt J, Kluczewska E, Kozinska-Marek E. Usefulness assessment of preoperative MRI fistulography in patients with perianal fistulas. Pol J Radiol. 2011 Oct. 76(4):40-4. [Medline]. [Full Text].

  32. Corman ML. Colon and Rectal Surgery. 4th ed. Philadelphia, Pa: Lippincott-Raven; 1998. 224-71.

  33. Dozois RR, Nichols JR. Surgery of the Colon and Rectum. New York, NY: Churchill Livingstone; 1997. 255-84.

  34. Lunniss PJ, Phillips RKS. Anal Fistula: Surgical Evaluation and Management. London, England: Chapman & Hall; 1996. 1-183.

  35. Nelson R. Anorectal abscess fistula: what do we know?. Surg Clin North Am. 2002 Dec. 82(6):1139-51, v-vi. [Medline].

  36. Gordon PH, Nivatvongs S, eds. Principles and Practice of Surgery for the Colon, Rectum and Anus. St Louis, Mo: Quality Medical Pub; 1999. 241-86.

  37. Peng KT, Hsieh MC, Hsu WH, Li YY, Yeh CH. Anterior ilioinguinal incision for drainage of high-located perianal abscess. Tech Coloproctol. 2012 Sep 28. [Medline].

  38. Buddicom E, Jamieson A, Beasley S, King S. Perianal abscess in children: aiming for optimal management. ANZ J Surg. 2012 Jan-Feb. 82(1-2):60-2. [Medline].

  39. Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg. 2005 May. 241(5):796-801; discussion 801-2. [Medline]. [Full Text].

  40. Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol. 2008 Jun. 12(2):111-7. [Medline].

  41. Malik AI, Nelson RL. Surgical management of anal fistulae: a systematic review. Colorectal Dis. 2008 Jun. 10(5):420-30. [Medline].

  42. Yeung JM, Alistair J, Simpson D, et al. Fibrin glue for the treatment of fistulae in ano - a method worth sticking to?. Colorectal Dis. 2009 Feb 7. [Medline].

  43. Gupta PJ. Anal fistulotomy using radiowaves- long-term outcome. Acta Chir Iugosl. 2008. 55(3):115-8. [Medline].

Illustration of major types of anorectal abscesses (submucosal type not pictured).
Goodsall rule for anorectal fistulas. Fistulas that exit in posterior half of rectum generally follow curved course toward posterior midline, whereas those that exit in anterior half of rectum usually follow radial course to dentate line.
Goodsall rule for anorectal fistulas. Note curved nature of posterior fistulas and radial (straight) orientation of anterior fistulas.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.